反应详情

TFA (0.215 mL, 2.80 mmol) was added to solution of 2,2-difluoro-N-(3-(5-(2-methylmorpholino)-1H-benzo[d]imidazol-2-yl)-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-5-yl)cyclopropanecarboxamide (15 mg, 0.028 mmol) in CH2Cl2 (5 mL). The reaction mixture was stirred overnight at room temperature, and then the solvent was removed in vacuo. Purification by flash chromatography (5% CH3OH/CH2Cl2) afforded the title compound (9 mg) as a solid. 1H NMR: (400 MHz, CD3OD): δ 8.44 (d, 1H, J=0.8 Hz), 7.64 (dd, 1H, J=1.6 and 8.8 Hz), 7.58-7.54 (m, 2H), 7.17 (d, 1H, J=1.6 Hz), 7.04 (dd, 1H, J=2.0 and 8.8 Hz), 3.99 (m, 1H), 3.82 (m, 2H), 3.52 (m, 1H), 3.44 (m, 1H), 2.84-2.70 (m, 2H), 2.47 (m, 1H), 2.12 (m, 1H), 1.85 (m, 1H), 1.24 (d, 3H, J=6.0 Hz); ESI-MS [M+H]+: 453.1.

1. customthe solvent was removed in vacuo
2. customPurification by flash chromatography (5% CH3OH/CH2Cl2)